Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)

Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)

Despite the profound changes and improvements reached in the field of HIV treatment, tolerability and adherence to highly active antiretroviral therapy remains a challenge. Furthermore, multi-experienced patients could take advantage of drugs with different mechanisms of action to combat the spread...

Full description

Saved in:
Bibliographic Details
Published in:Molecular medicine reports Vol. 19; no. 3; pp. 1987 - 1995
Main Authors: Rullo, Emmanuele Venanzi, Ceccarelli, Manuela, Condorelli, Fabrizio, Facciola, Alessio, Visalli, Giuseppa, Daleo, Francesco, Paolucci, Ivana, Cacopardo, Bruno, Pinzone, Marilia Rita, Di Rosa, Michele, Nunnari, Giuseppe, Pellicano, Giovanni F
Format: Journal Article
Language:English
Published: Athens Spandidos Publications 01-03-2019
Spandidos Publications UK Ltd
Subjects:
Acquired immune deficiency syndrome
AIDS
AIDS treatment
Anti-HIV agents
Antiretroviral agents
Antiretroviral drugs
Antiviral agents
Antiviral drugs
Atazanavir
Cells (Biology)
Chemokines
Clinical trials
Conferences and conventions
Darunavir
Drug resistance
Drug therapy
Drugs
Efavirenz
Enfuvirtide
Highly active antiretroviral therapy
HIV
Human immunodeficiency virus
Infections
Maraviroc
Medical research
Morbidity
Pharmaceutical research
Prevention
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the profound changes and improvements reached in the field of HIV treatment, tolerability and adherence to highly active antiretroviral therapy remains a challenge. Furthermore, multi-experienced patients could take advantage of drugs with different mechanisms of action to combat the spread of resistance to actual therapy. For these reasons identification of new HIV drugs is crucial. Among all the molecules that at present are under investigation, entry and fusion inhibitors pose an interesting class owing to their peculiar characteristics, including prevention of entry of the virus into the human cells. In this study, we reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1791-2997
1791-3004
DOI:10.3892/mmr.2019.9840